Literature DB >> 18468229

Artificial cells for the development of cell therapy.

Naoya Kobayashi1.   

Abstract

In developing cell therapy, normal human cells are ideal as a cell source, but considering the serious lack of donor organs, it is unlikely to obtain a large enough amount of human cells. Moreover, even with current culturing techniques, the long-term culturing of normal human cells is difficult. On the other hand, in using xenogenic porcine cells and human tumor tissue-derived cell lines, there is concern that species-specific pathogens can be transmitted (such as infection by porcine endogenous retroviruses), and possible cancer may thus develop in recipients. Therefore, we are making efforts toward establishing reversible immortalized human cell lines that can be economically grown in tissue culture using the techniques of gene transfer in order to solve these problems. I here describe a strategy for establishing human reversibly immortalized cell lines that are intended for practical application in cell therapies. I would like to further contribute toward the realization of tissue engineering in fusional coordination with cell-processing technology by the utilization of such cell line constructing techniques.

Entities:  

Mesh:

Year:  2008        PMID: 18468229     DOI: 10.3727/000000008783907099

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  5 in total

1.  Porcine hepatocyte isolation and reversible immortalization mediated by retroviral transfer and site-specific recombination.

Authors:  Fan Ying Meng; Zhi Shui Chen; Meng Han; Xin Peng Hu; Xing Xing He; Yong Liu; Wen Tao He; Wei Huang; Hui Guo; Ping Zhou
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 2.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

3.  In vitro small intestinal epithelial cell growth on a nanocomposite polycaprolactone scaffold.

Authors:  Ashish Gupta; Dina S Vara; Geoffrey Punshon; Kevin M Sales; Marc C Winslet; Alexander M Seifalian
Journal:  Biotechnol Appl Biochem       Date:  2009-12-04       Impact factor: 2.431

4.  Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials.

Authors:  Kazuhiko Yamada; Jigesh A Shah; Tatsu Tanabe; Miguel A Lanaspa; Richard J Johnson
Journal:  Curr Transplant Rep       Date:  2017-05-08

5.  Hepatocyte isolation from resected benign tissues: Results of a 5-year experience.

Authors:  Fan-Ying Meng; Li Liu; Jun Liu; Chun-You Li; Jian-Ping Wang; Feng-Hui Yang; Zhi-Shui Chen; Ping Zhou
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.